Oncogenic activation of K-Ras has been reported as a prognostic marker of poor outcome in NSCLC patients and K-Ras mutations seemed to be associated with a shorter survival in early-stage and locally advanced NSCLC (Fukuyama et al, 1997; Huncharek et al, 1999). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.